Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy. It Is Worth To Decide!

• DOI: 10.5200/sm-hs.2016.077
• Publication Date: 2016-12-22T14:30:39Z
• Authors: Agnė Čižauskaitė; Donatas Petrauskas; Dainius Šimčikas; Alvydas Česas
• Keywords: Neoadjuvant Therapy; Axilla

Objective. To evaluate the predictable percentage of patients that could be eligible for sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in Klaipeda University Hospital Breast Surgery Department. Background. Although SLNB is a standard staging method axillar status assessment early- stage clinically (LN) negative breast cancer patients, NAC still controversial. Axillary dissection (ALND) remains accepted surgical approach following regardless primary LN status. ALND associated with significant morbidity and complications. now used increasing frequency not only locally advanced but also early-stage optimal indications are required. Methods. 163 cases treated by were enrolled this study. After all at time definitive surgery, underwent ALND. Results. Before NAC, clinical was 21 (13%) positive 141 (87%). When evaluated postoperatively, pN0 group detected (100%). Meanwhile group, 63 (44.7%) pN+ 78 (55.3%) cases. Conclusions. should always performed before or patients. Optimal technique chosen node- to assure success procedure.